These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 27302328)
21. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study. Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283 [TBL] [Abstract][Full Text] [Related]
22. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. Yih WK; Kulldorff M; Sandhu SK; Zichittella L; Maro JC; Cole DV; Jin R; Kawai AT; Baker MA; Liu C; McMahill-Walraven CN; Selvan MS; Platt R; Nguyen MD; Lee GM Pharmacoepidemiol Drug Saf; 2016 May; 25(5):481-92. PubMed ID: 26572776 [TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis. Minozzi S; Lytras T; Gianola S; Gonzalez-Lorenzo M; Castellini G; Galli C; Cereda D; Bonovas S; Pariani E; Moja L EClinicalMedicine; 2022 Apr; 46():101331. PubMed ID: 35360146 [TBL] [Abstract][Full Text] [Related]
24. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial. Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M; Vaccine; 2015 Jan; 33(4):535-41. PubMed ID: 25488331 [TBL] [Abstract][Full Text] [Related]
25. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
26. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older. Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177 [TBL] [Abstract][Full Text] [Related]
27. Differential gene expression elicited by children in response to the 2015-16 live attenuated versus inactivated influenza vaccine. Cole KS; Martin JM; Horne WT; Lin CJ; Nowalk MP; Alcorn JF; Zimmerman RK Vaccine; 2017 Dec; 35(49 Pt B):6893-6897. PubMed ID: 29132989 [TBL] [Abstract][Full Text] [Related]
28. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016. Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883 [TBL] [Abstract][Full Text] [Related]
29. Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15. Florek K; Mutschler J; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC Vaccine; 2020 Feb; 38(8):2088-2094. PubMed ID: 31753674 [TBL] [Abstract][Full Text] [Related]
30. Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma. Nordin JD; Vazquez-Benitez G; Olsen A; Kuckler LC; Gao AY; Kharbanda EO Vaccine; 2019 Jul; 37(30):4055-4060. PubMed ID: 31196683 [TBL] [Abstract][Full Text] [Related]
31. Feasibility of Text Message Influenza Vaccine Safety Monitoring During Pregnancy. Stockwell MS; Cano M; Jakob K; Broder KR; Gyamfi-Bannerman C; Castaño PM; Lewis P; Barrett A; Museru OI; Castellanos O; LaRussa PS Am J Prev Med; 2017 Sep; 53(3):282-289. PubMed ID: 28495223 [TBL] [Abstract][Full Text] [Related]
33. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Ray GT; Lewis N; Goddard K; Ross P; Duffy J; DeStefano F; Baxter R; Klein NP Vaccine; 2017 May; 35(20):2668-2675. PubMed ID: 28404355 [TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine. Shim E; Brown ST; DePasse J; Nowalk MP; Raviotta JM; Smith KJ; Zimmerman RK Am J Prev Med; 2016 Sep; 51(3):309-17. PubMed ID: 27079638 [TBL] [Abstract][Full Text] [Related]
35. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study. Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B; Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278 [TBL] [Abstract][Full Text] [Related]
37. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Oct; 43(10):1515-1544. PubMed ID: 36456484 [TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study. Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435 [TBL] [Abstract][Full Text] [Related]
39. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026 [TBL] [Abstract][Full Text] [Related]
40. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season. de la Cueva IS; Gerber JE; Hastie A; Brotons C; Panzer F; Pirçon JY; Talsma P; Eckermann T; Nikic V; Gomez XM; Alsdurf H Drug Saf; 2024 Nov; 47(11):1137-1148. PubMed ID: 38949714 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]